Pharvaris to Participate in 11th Annual SVB Leerink Global Healthcare Conference
Pharvaris (Nasdaq: PHVS), a clinical-stage company, announced its participation in the 11th Annual SVB Leerink Global Healthcare Conference, occurring virtually from February 14–18, 2022.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Pharvaris (Nasdaq: PHVS), a clinical-stage company, announced its participation in the 11th Annual SVB Leerink Global Healthcare Conference, occurring virtually from February 14–18, 2022. The fireside chat is set for February 16 at 4:40 PM CEST (10:40 AM EST). A live audio webcast will be accessible on the Investors section of their website, with a replay available for 30 days post-event. Pharvaris focuses on developing oral bradykinin-B2-receptor antagonists targeting hereditary angioedema and aims to provide alternatives to existing injected therapies.
Details
News Market Reaction – PHVS
The recorded move for PHVS in the trading session of this news was -4.68%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
ZUG, Switzerland, Feb. 09, 2022 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company focused on the development and commercialization of novel oral bradykinin-B2-receptor antagonists for the treatment of hereditary angioedema (HAE) and other bradykinin-B2-receptor-mediated indications, today announced that management will participate in a fireside chat at the 11th Annual SVB Leerink Global Healthcare Conference taking place virtually from February 14–18, 2022.
The fireside chat will take place on Wednesday, February 16 at 4:40 PM CEST (10:40 AM EST). A live audio webcast will be available on the Investors section of the Pharvaris website at: https://ir.pharvaris.com/news-events/events-presentations. A replay will be available on Pharvaris’ website for 30 days following the presentation.
About Pharvaris
Pharvaris is a clinical-stage company focused on bringing oral bradykinin-B2-receptor antagonists to patients. By targeting this clinically proven therapeutic target with novel small molecules, the Pharvaris team is advancing new alternatives to injected therapies for all sub-types of HAE and other bradykinin-mediated diseases. The Company brings together executives with a breadth of expertise across pharmaceutical development and rare disorders, including HAE. For more information, visit https://pharvaris.com/.
For more information:
Pharvaris
Maryann Cimino
Director of Corporate Relations
+1-617-710-7305
maryann.cimino@pharvaris.com
Investor Contact
Sarah McCabe
Stern Investor Relations, Inc.
+1-212-362-1200
sarah.mccabe@sternir.com
Media Contact
Maggie Beller
Russo Partners, LLC
+1-646-942-5631
maggie.beller@russopartnersllc.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.